MatthewJoshuaFrankMD

Clinical Fellow in Medicine, Beth Israel Deaconess Medical Center

Dr. Frank is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
David Geffen School of Medicine at UCLAClass of 2011

PubMed

Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
Surbhi Sidana, Andriyana K Bankova, Hitomi Hosoya, Shaji K Kumar, Tyson H Holmes
Blood Cancer Journal. 2024-10-09
Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series
Jack J Scala, Michael J Eckrich, Keagan Lipak, Bonnie Yates, Constance Yuan
Haematologica. 2024-10-01
Management of post-autologous transplant relapse in patients with T-cell lymphomas.
Olivier Veilleux, Francisco Socola, Sally Arai, Matthew J Frank, Laura Johnston
American Journal of Hematology. 2024-08-01

Abstracts/Posters

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018